In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vertex nets $390.1mm through sale of common shares and debt

Executive Summary

Vertex Pharmaceuticals (infectious and immune diseases and cancer) has netted $112.1mm through the follow-on public offering of 6.9mm common shares (including the overallotment) at $17.14. The company also concurrently netted $278.5mm by selling 4.75% five-year convertible senior subordinated notes which convert into 43.22 common shares per $1k in notes (about $23.14 per share).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • FOPO

Related Companies